Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NN-840
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance NN-840
Details : The proceeds will support development of its innovative TNF-alpha inhibitor NN-840 program for Alzheimer’s disease and other neurodegenerative conditions.
Product Name : NN-840
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 10, 2025
Lead Product(s) : NN-840
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding